Isosorbide Mononitrate vs Dinitrate for Chronic Angina Prophylaxis
For chronic prophylaxis of angina, isosorbide mononitrate is preferred over isosorbide dinitrate due to superior convenience with once-daily dosing, better tolerability (particularly less headache), improved patient compliance, and equivalent or superior antianginal efficacy.
Pharmacokinetic Advantages of Mononitrate
Isosorbide mononitrate is the active metabolite of isosorbide dinitrate, which means it bypasses hepatic first-pass metabolism 1. This provides more predictable bioavailability and allows for:
- Once-daily dosing with sustained-release formulations (60-240 mg daily) providing 12-24 hour coverage 2, 3, 4
- Twice-daily dosing with immediate-release formulations (20 mg BID) 2, 3, 4
In contrast, isosorbide dinitrate requires:
- 2-3 times daily dosing (5-80 mg, 2-3 times daily for immediate-release) 2, 3, 4
- 1-2 times daily for slow-release formulations (40 mg) 2, 3, 4
Clinical Efficacy Evidence
Direct comparative studies demonstrate mononitrate's superiority:
A randomized crossover trial showed that once-daily isosorbide-5-mononitrate (50-100 mg) provided sustained antianginal effect throughout the day, while the effect of isosorbide dinitrate diminished by the end of the 3-week treatment period, with nitroglycerin requirements substantially rising 5
Another randomized double-blind crossover study found that controlled-release isosorbide-5-mononitrate 60 mg once daily resulted in significantly fewer signs of myocardial ischemia compared to conventional isosorbide dinitrate 20 mg three times daily 6
Both drugs showed similar improvements in exercise tolerance initially, but mononitrate's effect lasted longer without evidence of tolerance 5, 7
Tolerability Profile
Headache—the primary limiting side effect of nitrates—is significantly less problematic with mononitrate:
In the crossover study, headache attacks increased progressively during dinitrate treatment but decreased by the end of mononitrate treatment 5
A comparative trial reported headache incidence of 40-41% with isosorbide dinitrate and mononitrate preparations versus 9.5% with alternative therapy, with nitrate-related headache being the main reason for study withdrawal 8
The improved tolerability profile translates to better long-term adherence 7
Practical Dosing Algorithm
Initial therapy:
- Start with isosorbide mononitrate sustained-release 60 mg once daily in the morning 2, 3, 4
- This provides effective prophylaxis for approximately 12 hours, covering the typical period of daily activity 7
If inadequate response after 2 weeks:
Tolerance prevention:
- The once-daily morning dosing inherently provides a nitrate-free interval overnight (approximately 12 hours), which prevents tolerance development 2, 3, 4
- This is a critical advantage over multiple-daily-dosing regimens with dinitrate
Important Caveats
Absolute contraindications apply to both formulations:
- Do not use within 24 hours of sildenafil or vardenafil, or 48 hours of tadalafil due to risk of profound hypotension and death 2, 3, 4
- Avoid in systolic BP <90 mmHg or >30 mmHg below baseline 2, 3, 4
- Not recommended in hypertrophic cardiomyopathy 9
Clinical context:
- Both formulations are indicated for prevention, not acute treatment of angina 10, 1
- Should be combined with beta-blockers when possible to prevent reflex tachycardia 2, 3, 11
- Neither nitrate formulation has been shown to reduce mortality or MI risk—they are purely symptomatic therapy 12, 13
Rebound phenomenon:
- Abrupt discontinuation may exacerbate anginal symptoms 7
- Taper gradually if stopping long-term therapy